* Neuropace Inc NPCE.OQ NPCE.O is expected to show a
rise in
quarterly revenue when it reports results on March 5 for the
period ending December 31 2023
* The Mountain View California-based company is expected to
report a 36.5% increase in revenue to $17.457 million from
$12.79 million a year ago, according to the mean estimate from 6
analysts, based on LSEG data. (Revenue is on Total Revenue.)
* LSEG's mean analyst estimate for Neuropace Inc is for a
loss
of 31 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Neuropace
Inc is
$16.00, below its last closing price of $16.17.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.41 -0.41 -0.28 Beat 31.7
Jun. 30 2023 -0.46 -0.46 -0.36 Beat 22.6
Mar. 31 2023 -0.46 -0.46 -0.41 Beat 10.1
Dec. 31 2022 -0.50 -0.49 -0.45 Beat 9.1
Sep. -0.52 -0.53 -0.48 Beat 8.9
30 2022
Jun. 30 2022 -0.44 -0.44 -0.52 Missed -17.3
Mar. 31 2022 -0.45 -0.44 -0.47 Missed -6.2
Dec. 31 2021 -0.32 -0.33 -0.44 Missed -33.3
This summary was machine generated March 1 at 21:59 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)